Impact of the COVID-19 pandemic on long-term trends in the prevalence of diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes: an international multicentre study based on data from 13 national diabetes registries.
Journal
The lancet. Diabetes & endocrinology
ISSN: 2213-8595
Titre abrégé: Lancet Diabetes Endocrinol
Pays: England
ID NLM: 101618821
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
10
05
2022
revised:
10
08
2022
accepted:
16
08
2022
pubmed:
7
10
2022
medline:
2
11
2022
entrez:
6
10
2022
Statut:
ppublish
Résumé
An increased prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes in children was observed in various diabetes centres worldwide during the COVID-19 pandemic. We aimed to evaluate trends in the prevalence of diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes before and during the COVID-19 pandemic, and to identify potential predictors of changes in diabetic ketoacidosis prevalence during the pandemic. For this international multicentre study, we used data from 13 national diabetes registries (Australia, Austria, Czechia, Denmark, Germany, Italy, Luxembourg, New Zealand, Norway, Slovenia, Sweden, USA [Colorado], and Wales). The study population comprised 104 290 children and adolescents aged 6 months to younger than 18 years, who were diagnosed with type 1 diabetes between Jan 1, 2006, and Dec 31, 2021. The observed diabetic ketoacidosis prevalence in 2020 and 2021 was compared to predictions based on trends over the pre-pandemic years 2006-19. Associations between changes in diabetic ketoacidosis prevalence and the severity of the COVID-19 pandemic and containment measures were examined with excess all-cause mortality in the whole population and the Stringency Index from the Oxford COVID-19 Government Response Tracker. 87 228 children and adolescents were diagnosed with type 1 diabetes between 2006 and 2019, 8209 were diagnosed in 2020, and 8853 were diagnosed in 2021. From 2006 to 2019, diabetic ketoacidosis at diagnosis of type 1 diabetes was present in 23 775 (27·3%) of 87 228 individuals and the mean annual increase in the prevalence of diabetic ketoacidosis in the total cohort from 2006 to 2019 was 1·6% (95% CI 1·3 to 1·9). The adjusted observed prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes was 39·4% (95% CI 34·0 to 45·6) in 2020 and 38·9% (33·6 to 45·0) in 2021, significantly higher than the predicted prevalence of 32·5% (27·8 to 37·9) for 2020 and 33·0% (28·3 to 38·5) for 2021 (p<0·0001 for both years). The prevalence of diabetic ketoacidosis was associated with the pandemic containment measures, with an estimated risk ratio of 1·037 (95% CI 1·024 to 1·051; p<0·0001) per ten-unit increase in the Stringency Index for 2020 and 1·028 (1·009 to 1·047; p=0·0033) for 2021, but was not significantly associated with excess all-cause mortality. During the COVID-19 pandemic, there was a marked exacerbation of the pre-existing increase in diabetic ketoacidosis prevalence at diagnosis of type 1 diabetes in children. This finding highlights the need for early and timely diagnosis of type 1 diabetes in children and adolescents. German Federal Ministry for Education and Research, German Robert Koch Institute, German Diabetes Association, German Diabetes Foundation, Slovenian Research Agency, Welsh Government, Central Denmark Region, and Swedish Association of Local Authorities and Regions.
Sections du résumé
BACKGROUND
An increased prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes in children was observed in various diabetes centres worldwide during the COVID-19 pandemic. We aimed to evaluate trends in the prevalence of diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes before and during the COVID-19 pandemic, and to identify potential predictors of changes in diabetic ketoacidosis prevalence during the pandemic.
METHODS
For this international multicentre study, we used data from 13 national diabetes registries (Australia, Austria, Czechia, Denmark, Germany, Italy, Luxembourg, New Zealand, Norway, Slovenia, Sweden, USA [Colorado], and Wales). The study population comprised 104 290 children and adolescents aged 6 months to younger than 18 years, who were diagnosed with type 1 diabetes between Jan 1, 2006, and Dec 31, 2021. The observed diabetic ketoacidosis prevalence in 2020 and 2021 was compared to predictions based on trends over the pre-pandemic years 2006-19. Associations between changes in diabetic ketoacidosis prevalence and the severity of the COVID-19 pandemic and containment measures were examined with excess all-cause mortality in the whole population and the Stringency Index from the Oxford COVID-19 Government Response Tracker.
FINDINGS
87 228 children and adolescents were diagnosed with type 1 diabetes between 2006 and 2019, 8209 were diagnosed in 2020, and 8853 were diagnosed in 2021. From 2006 to 2019, diabetic ketoacidosis at diagnosis of type 1 diabetes was present in 23 775 (27·3%) of 87 228 individuals and the mean annual increase in the prevalence of diabetic ketoacidosis in the total cohort from 2006 to 2019 was 1·6% (95% CI 1·3 to 1·9). The adjusted observed prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes was 39·4% (95% CI 34·0 to 45·6) in 2020 and 38·9% (33·6 to 45·0) in 2021, significantly higher than the predicted prevalence of 32·5% (27·8 to 37·9) for 2020 and 33·0% (28·3 to 38·5) for 2021 (p<0·0001 for both years). The prevalence of diabetic ketoacidosis was associated with the pandemic containment measures, with an estimated risk ratio of 1·037 (95% CI 1·024 to 1·051; p<0·0001) per ten-unit increase in the Stringency Index for 2020 and 1·028 (1·009 to 1·047; p=0·0033) for 2021, but was not significantly associated with excess all-cause mortality.
INTERPRETATION
During the COVID-19 pandemic, there was a marked exacerbation of the pre-existing increase in diabetic ketoacidosis prevalence at diagnosis of type 1 diabetes in children. This finding highlights the need for early and timely diagnosis of type 1 diabetes in children and adolescents.
FUNDING
German Federal Ministry for Education and Research, German Robert Koch Institute, German Diabetes Association, German Diabetes Foundation, Slovenian Research Agency, Welsh Government, Central Denmark Region, and Swedish Association of Local Authorities and Regions.
Identifiants
pubmed: 36202118
pii: S2213-8587(22)00246-7
doi: 10.1016/S2213-8587(22)00246-7
pmc: PMC9597608
pii:
doi:
Types de publication
Multicenter Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
786-794Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests We declare no competing interests.
Références
Diabetologia. 2020 Aug;63(8):1530-1541
pubmed: 32382815
Pediatr Diabetes. 2022 Jun;23(4):433-438
pubmed: 35218124
Pediatr Diabetes. 2021 Sep;22(6):900-908
pubmed: 33978305
Pediatr Diabetes. 2018 Oct;19 Suppl 27:155-177
pubmed: 29900641
Diabetes Care. 2019 Mar;42(3):443-449
pubmed: 30573652
Lancet. 2007 Oct 20;370(9596):1453-7
pubmed: 18064739
Nat Hum Behav. 2021 Apr;5(4):529-538
pubmed: 33686204
Horm Res Paediatr. 2022;95(4):393-396
pubmed: 35780775
Diabetes Care. 2022 Aug 1;45(8):1762-1771
pubmed: 35043145
Pediatr Diabetes. 2022 Feb;23(1):10-18
pubmed: 34865288
JAMA. 2020 Aug 25;324(8):801-804
pubmed: 32702751
Lancet Diabetes Endocrinol. 2022 Aug;10(8):589-596
pubmed: 35803296
Pediatr Diabetes. 2021 Jun;22(4):552-557
pubmed: 33745226
Front Endocrinol (Lausanne). 2022 Mar 09;13:856958
pubmed: 35355556
Front Pediatr. 2022 Feb 14;10:820156
pubmed: 35237540
JAMA Cardiol. 2020 Oct 1;5(10):1154-1163
pubmed: 32558876
Elife. 2021 Jun 30;10:
pubmed: 34190045
JAMA Pediatr. 2022 Apr 1;176(4):414-415
pubmed: 35072727
Pediatr Diabetes. 2022 Sep;23(6):749-753
pubmed: 35366047
Diabetes Care. 2020 Nov;43(11):2768-2775
pubmed: 32962981
Diabet Med. 2021 Jan;38(1):e14417
pubmed: 33020999
J Pediatr. 2010 Mar;156(3):472-7
pubmed: 19962155
Endocrinol Metab Clin North Am. 2000 Dec;29(4):657-82
pubmed: 11149156
Nat Rev Dis Primers. 2020 May 14;6(1):40
pubmed: 32409703
Diabetes Care. 2021 Jul;44(7):1540-1546
pubmed: 33990377
ESC Heart Fail. 2021 Feb;8(1):333-343
pubmed: 33283476